Your browser does not support JavaScript capabilities, which maybe required to display this page properly.


PDF FormatRequires Adobe Acrobat Reader

Table 6.6b

Immunosuppression Use for Induction by Discharge Regimen, 2004 to 2008

Recipients with Pancreas Transplant Alone (PTA) Transplants

  Discharge Regimen (w/ or w/o Steroids Use) All
CyA Tac CyA+ MMF Tac+ MMF Tac+ Aza Siro+ MMF CyA+ Siro Tac+ Siro Other
Functioning Graft with Immunosuppression Info at Discharge 1 277 6 398 4 2 2 61 136 887
% of All Regimens 0.1% 31.2% 0.7% 44.9% 0.5% 0.2% 0.2% 6.9% 15.3% 100.0%
Induction Drug 0.0% 0.0% 0.0% 2.3% 0.0% 0.0% 0.0% 0.0% 0.7% 1.1%
Atgam/NRATG/NRATS
OKT3 0.0% 4.7% 0.0% 5.3% 0.0% 0.0% 0.0% 3.3% 4.4% 4.7%
Thymoglobulin 0.0% 10.5% 100.0% 61.6% 25.0% 50.0% 100.0% 16.4% 111.0% 50.2%
Zenapax 0.0% 15.2% 16.7% 4.5% 0.0% 0.0% 0.0% 4.9% 7.4% 8.3%
Simulect 100.0% 0.7% 0.0% 4.8% 0.0% 0.0% 0.0% 0.0% 2.2% 2.8%
Campath 0.0% 28.5% 16.7% 15.3% 50.0% 0.0% 0.0% 45.9% 44.9% 26.2%
No Induction Drugs Recorded 0.0% 45.1% 0.0% 14.8% 25.0% 50.0% 0.0% 36.1% 11.0% 25.1%


Source: OPTN/SRTR Data as of May 4, 2009.

Individual induction drug percentages will not necessarily add up to 100 percent, as patients may be prescribed more than one induction drug.

CyA: Cyclosporine; Tac: Tacrolimus; MMF: Include MMF(Mycophenolate Mofetil) and MPA(Mycophenolate Sodium); Aza: Azathioprine; Siro: Sirolimus.



PDF FormatRequires Adobe Acrobat Reader